Neurocrine Biosciences Inc (NBIX)

Debt-to-equity ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	—	—	—	169,500	0	0	169,000	377,700	335,100	330,700	326,300	322,000	317,900	425,000	419,500	414,100	408,807	403,589	398,466	393,435
Total stockholders’ equity	US$ in thousands	2,232,000	2,002,100	1,853,000	1,684,500	1,707,800	1,544,600	1,423,400	1,391,100	1,374,000	1,346,000	1,279,200	1,205,600	1,126,200	804,300	831,200	700,300	636,900	574,500	483,700	409,300
Debt-to-equity ratio		0.00	0.00	0.00	0.10	0.00	0.00	0.12	0.27	0.24	0.25	0.26	0.27	0.28	0.53	0.50	0.59	0.64	0.70	0.82	0.96

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $2,232,000K
= 0.00

The debt-to-equity ratio of Neurocrine Biosciences, Inc. has shown a decreasing trend over the quarters in question, starting at 0.27 in Q1 2022 and gradually decreasing to 0.08 in Q4 2023. This indicates that the company has been reducing its reliance on debt to finance its operations and growth. A lower debt-to-equity ratio is generally viewed positively as it suggests lower financial risk and greater financial stability. Neurocrine Biosciences, Inc.'s consistent decrease in this ratio reflects a prudent approach to managing its capital structure and signifies a healthier balance between debt and equity in its financing mix. Overall, the decreasing trend in the debt-to-equity ratio for Neurocrine Biosciences, Inc. suggests the company is effectively managing its debt levels and maintaining a sound financial position.